Publications by Kjersti Flatmark
142 publications found
Original articles
Short-term results after robot-assisted surgery for primary rectal cancers requiring beyond total mesorectal excision in multiple compartments
Scand J Surg, 113 (1), 3-12
DOI 10.1177/14574969231200654, PubMed 37787437
Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma
Cancer Res, 83 (19), 3184-3191
DOI 10.1158/0008-5472.CAN-23-0013, PubMed 37433032
Navigation-Assisted Surgery for Locally Advanced Primary and Recurrent Rectal Cancer
Ann Surg Oncol, 30 (12), 7602-7611
DOI 10.1245/s10434-023-13964-9, PubMed 37481493
External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
Eur J Surg Oncol, 49 (8), 1481-1488
DOI 10.1016/j.ejso.2023.03.206, PubMed 36935222
A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
Cancer Res Commun, 3 (2), 235-244
DOI 10.1158/2767-9764.CRC-22-0295, PubMed 36968142
Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models
Nanomedicine, 48, 102656
DOI 10.1016/j.nano.2023.102656, PubMed 36646195
T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases
Gigascience, 12
DOI 10.1093/gigascience/giad032, PubMed 37161965
Alginate Microsphere Encapsulation of Drug-Loaded Nanoparticles: A Novel Strategy for Intraperitoneal Drug Delivery
Mar Drugs, 20 (12)
DOI 10.3390/md20120744, PubMed 36547891
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
Br J Cancer, 127 (12), 2227-2233
DOI 10.1038/s41416-022-02004-0, PubMed 36229579
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
Acta Oncol, 61 (8), 955-962
DOI 10.1080/0284186X.2022.2098053, PubMed 35943168
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
JCO Precis Oncol, 6 (1), e2200015
DOI 10.1200/PO.22.00015, PubMed 35476549
A comprehensive framework for analysis of microRNA sequencing data in metastatic colorectal cancer
NAR Cancer, 4 (1), zcab051
DOI 10.1093/narcan/zcab051, PubMed 35047825
MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts
Acta Oncol, 61 (2), 255-263
DOI 10.1080/0284186X.2021.2013530, PubMed 34918621
Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients
Br J Cancer, 126 (5), 726-735
DOI 10.1038/s41416-021-01620-6, PubMed 34887523
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
J Immunother Cancer, 9 (10)
DOI 10.1136/jitc-2021-003109, PubMed 34711663
Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer
Front Oncol, 11, 671629
DOI 10.3389/fonc.2021.671629, PubMed 34178659
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale
Cancers (Basel), 13 (11)
DOI 10.3390/cancers13112819, PubMed 34198773
Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Ann Surg Oncol, 28 (9), 5252-5262
DOI 10.1245/s10434-021-10022-0, PubMed 34019185
Metastases in locally advanced rectal cancer undergoing curatively intended treatment
Eur J Surg Oncol, 47 (9), 2377-2383
DOI 10.1016/j.ejso.2021.04.023, PubMed 34049768
The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer
Br J Cancer, 125 (2), 240-246
DOI 10.1038/s41416-021-01377-y, PubMed 33837301
Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
Sci Rep, 11 (1), 6731
DOI 10.1038/s41598-021-86239-6, PubMed 33762676
Long-Term Oncologic Outcomes After Laparoscopic Versus Open Resection for Colorectal Liver Metastases : A Randomized Trial
Ann Intern Med, 174 (2), 175-182
DOI 10.7326/M20-4011, PubMed 33197213
Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method
Ann Surg Oncol, 28 (1), 252-257
DOI 10.1245/s10434-020-08655-8, PubMed 32488520
Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
Transl Oncol, 13 (8), 100793
DOI 10.1016/j.tranon.2020.100793, PubMed 32447231
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases
Cancer Biol Ther, 21 (5), 432-440
DOI 10.1080/15384047.2020.1721252, PubMed 32098573
MirGeneDB 2.0: the metazoan microRNA complement
Nucleic Acids Res, 48 (D1), D132-D141
DOI 10.1093/nar/gkz885, PubMed 31598695
Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
Cancer Immunol Immunother, 69 (3), 355-364
DOI 10.1007/s00262-019-02458-x, PubMed 31893287
Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
Acta Oncol, 59 (4), 404-409
DOI 10.1080/0284186X.2019.1704864, PubMed 31876430
Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?
Clin Transl Radiat Oncol, 21, 5-10
DOI 10.1016/j.ctro.2019.11.006, PubMed 31872084
Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei
Clin Exp Metastasis, 36 (6), 511-518
DOI 10.1007/s10585-019-09991-0, PubMed 31541325
Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
Transl Oncol, 12 (8), 1038-1044
DOI 10.1016/j.tranon.2019.04.014, PubMed 31146167
High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
BMC Cancer, 19 (1), 488
DOI 10.1186/s12885-019-5724-z, PubMed 31122213
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111
ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis
Eur J Surg Oncol, 47 (1), 134-138
DOI 10.1016/j.ejso.2019.04.014, PubMed 31036394
Laparoscopic versus open liver resection in the posterosuperior segments: a sub-group analysis from the OSLO-COMET randomized controlled trial
HPB (Oxford), 21 (11), 1485-1490
DOI 10.1016/j.hpb.2019.03.358, PubMed 30962136
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response
Cold Spring Harb Mol Case Stud, 5 (2)
DOI 10.1101/mcs.a003566, PubMed 30862609
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006
Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
J Control Release, 293, 183-192
DOI 10.1016/j.jconrel.2018.11.029, PubMed 30529259
Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer
Transl Oncol, 12 (1), 76-83
DOI 10.1016/j.tranon.2018.09.010, PubMed 30273860
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
Br J Cancer, 118 (10), 1322-1328
DOI 10.1038/s41416-018-0085-y, PubMed 29695770
Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement
Eur J Surg Oncol, 44 (8), 1226-1232
DOI 10.1016/j.ejso.2018.03.029, PubMed 29691115
Low dose-rate irradiation with [3H]-labelled valine to selectively target hypoxic cells in a human colorectal cancer xenograft model
Acta Oncol, 57 (9), 1216-1224
DOI 10.1080/0284186X.2018.1457223, PubMed 29630428
Vertical Rectus Abdominis Musculocutaneous Flap Repair Improves Perineal Wound Healing after Abdominoperineal Resection for Irradiated Locally Advanced Rectal Cancer
Ann Surg Oncol, 25 (5), 1357-1365
DOI 10.1245/s10434-018-6363-3, PubMed 29497909
Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial
Ann Surg, 267 (2), 199-207
DOI 10.1097/SLA.0000000000002353, PubMed 28657937
Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide
Oncotarget, 8 (44), 76921-76934
DOI 10.18632/oncotarget.20217, PubMed 29100358
Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
Oncotarget, 8 (44), 76290-76304
DOI 10.18632/oncotarget.19350, PubMed 29100312
Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
Pigment Cell Melanoma Res, 30 (5), 467-476
DOI 10.1111/pcmr.12599, PubMed 28513992
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694, PubMed 28977905
Pathway-based classification of breast cancer subtypes
Front Biosci (Landmark Ed), 22 (10), 1697-1712
DOI 10.2741/4566, PubMed 28410140
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
Ann Surg Oncol, 24 (7), 1916-1922
DOI 10.1245/s10434-017-5814-6, PubMed 28224367
Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival
Acta Oncol, 56 (6), 813-818
DOI 10.1080/0284186X.2017.1287951, PubMed 28464745
Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
Clin Exp Metastasis, 34 (1), 51-62
DOI 10.1007/s10585-016-9829-3, PubMed 27812769
Deep Pelvic Surgical Site Infection After Radiotherapy and Surgery for Locally Advanced Rectal Cancer
Ann Surg Oncol, 24 (3), 721-728
DOI 10.1245/s10434-016-5621-5, PubMed 27766561
Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
Br J Cancer, 115 (8), 929-939
DOI 10.1038/bjc.2016.278, PubMed 27599042
Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
Cancer Res Treat, 49 (2), 374-386
DOI 10.4143/crt.2016.080, PubMed 27488871
Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
BMC Cancer, 16, 536
DOI 10.1186/s12885-016-2601-x, PubMed 27461255
Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy
Cancer Med, 5 (8), 1840-9
DOI 10.1002/cam4.766, PubMed 27273130
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
Oncotarget, 7 (23), 34907-17
DOI 10.18632/oncotarget.8995, PubMed 27145458
Expression and clinical significance of Wee1 in colorectal cancer
Tumour Biol, 37 (9), 12133-12140
DOI 10.1007/s13277-016-5081-3, PubMed 27220319
Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort
J Surg Oncol, 114 (2), 222-7
DOI 10.1002/jso.24290, PubMed 27173150
Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
Radiother Oncol, 119 (3), 505-11
DOI 10.1016/j.radonc.2016.02.020, PubMed 26968754
Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: case report
World J Surg Oncol, 14, 63
DOI 10.1186/s12957-016-0818-4, PubMed 26940557
Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome
Clin Oncol (R Coll Radiol), 28 (8), 532-9
DOI 10.1016/j.clon.2016.01.014, PubMed 26888115
microRNAs as cancer biomarkers
Scand J Clin Lab Invest Suppl, 245, S80-3
DOI 10.1080/00365513.2016.1210330, PubMed 27542003
High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer
Radiother Oncol, 118 (2), 393-8
DOI 10.1016/j.radonc.2015.11.031, PubMed 26705680
Prophylactic mesh at end-colostomy construction reduces parastomal hernia rate: a randomized trial
Colorectal Dis, 17 (10), O191-7
DOI 10.1111/codi.13065, PubMed 26179984
Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
Clin Exp Metastasis, 32 (8), 755-67
DOI 10.1007/s10585-015-9742-1, PubMed 26349943
Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells
J Enzyme Inhib Med Chem, 31 (5), 779-86
DOI 10.3109/14756366.2015.1069286, PubMed 26244271
Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
BMC Cancer, 15, 543
DOI 10.1186/s12885-015-1557-6, PubMed 26205955
MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer
Br J Radiol, 88 (1051), 20150097
DOI 10.1259/bjr.20150097, PubMed 25899892
Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial
Trials, 16, 73
DOI 10.1186/s13063-015-0577-5, PubMed 25872027
High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
Eur J Cancer, 51 (1), 9-17
DOI 10.1016/j.ejca.2014.10.020, PubMed 25466510
B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome
BMC Cancer, 14, 602
DOI 10.1186/1471-2407-14-602, PubMed 25139714
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy
PLoS One, 9 (2), e89750
DOI 10.1371/journal.pone.0089750, PubMed 24587009
The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells
J Ovarian Res, 7, 23
DOI 10.1186/1757-2215-7-23, PubMed 24528603
Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis
J Surg Oncol, 109 (6), 521-6
DOI 10.1002/jso.23527, PubMed 24347444
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
Int J Radiat Oncol Biol Phys, 87 (4), 753-60
DOI 10.1016/j.ijrobp.2013.07.023, PubMed 24035332
Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer
Clin Colorectal Cancer, 12 (4), 261-6
DOI 10.1016/j.clcc.2013.06.003, PubMed 24012455
Clinical significance of disseminated tumour cells in non-small cell lung cancer
Br J Cancer, 109 (5), 1264-70
DOI 10.1038/bjc.2013.450, PubMed 23942067
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
Int J Cancer, 133 (6), 1497-506
DOI 10.1002/ijc.28158, PubMed 23494569
Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer
PLoS One, 8 (6), e66165
DOI 10.1371/journal.pone.0066165, PubMed 23824282
Nuclear legumain activity in colorectal cancer
PLoS One, 8 (1), e52980
DOI 10.1371/journal.pone.0052980, PubMed 23326369
Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
BMC Cancer, 12, 505
DOI 10.1186/1471-2407-12-505, PubMed 23121918
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
Radiat Oncol, 7, 165
DOI 10.1186/1748-717X-7-165, PubMed 23017053
EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
Br J Cancer, 107 (4), 667-74
DOI 10.1038/bjc.2012.293, PubMed 22782346
Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei
Eur J Surg Oncol, 38 (10), 969-76
DOI 10.1016/j.ejso.2012.06.552, PubMed 22763244
B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer
Int J Cancer, 131 (11), 2528-36
DOI 10.1002/ijc.27566, PubMed 22473715
Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
Virchows Arch, 460 (2), 193-202
DOI 10.1007/s00428-011-1191-x, PubMed 22249560
Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer
PLoS One, 7 (11), e50806
DOI 10.1371/journal.pone.0050806, PubMed 23226389
Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients
Tumour Biol, 33 (1), 73-83
DOI 10.1007/s13277-011-0247-5, PubMed 22006279
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination
Angiogenesis, 14 (4), 481-9
DOI 10.1007/s10456-011-9231-3, PubMed 21833622
Salvage surgery for locally recurrent rectal cancer: total mesorectal excision during the primary operation does not influence the outcome
Colorectal Dis, 13 (5), 506-11
DOI 10.1111/j.1463-1318.2010.02256.x, PubMed 20236148
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
Radiat Oncol, 6, 33
DOI 10.1186/1748-717X-6-33, PubMed 21473790
Disseminated tumour cells as a prognostic biomarker in colorectal cancer
Br J Cancer, 104 (9), 1434-9
DOI 10.1038/bjc.2011.97, PubMed 21448171
Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study
BMC Cancer, 10, 469
DOI 10.1186/1471-2407-10-469, PubMed 20809961
Nuclear S100A4 is a novel prognostic marker in colorectal cancer
Eur J Cancer, 46 (16), 2919-25
DOI 10.1016/j.ejca.2010.07.013, PubMed 20719498
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
Int J Radiat Oncol Biol Phys, 78 (2), 555-62
DOI 10.1016/j.ijrobp.2010.04.036, PubMed 20675069
TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
Tumour Biol, 32 (1), 1-12
DOI 10.1007/s13277-010-0073-1, PubMed 20652782
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
Lancet Oncol, 11 (5), 459-64
DOI 10.1016/S1470-2045(10)70058-9, PubMed 20378407
Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models
Hum Pathol, 41 (8), 1109-19
DOI 10.1016/j.humpath.2009.12.013, PubMed 20338618
Coexpression and nuclear colocalization of metastasis-promoting protein S100A4 and p53 without mutual regulation in colorectal carcinoma
Amino Acids, 41 (4), 875-84
DOI 10.1007/s00726-010-0514-6, PubMed 20191297
MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy
Radiother Oncol, 93 (2), 279-84
DOI 10.1016/j.radonc.2009.08.046, PubMed 19800704
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status
Int J Radiat Oncol Biol Phys, 74 (2), 546-52
DOI 10.1016/j.ijrobp.2009.01.068, PubMed 19427556
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
Tumour Biol, 30 (1), 15-25
DOI 10.1159/000199447, PubMed 19194111
The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications
BMC Cancer, 8, 172
DOI 10.1186/1471-2407-8-172, PubMed 18554396
Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy
Mol Cancer, 7, 33
DOI 10.1186/1476-4598-7-33, PubMed 18439252
Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients
Lung Cancer, 61 (2), 170-6
DOI 10.1016/j.lungcan.2007.12.018, PubMed 18261824
Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
Radiother Oncol, 86 (3), 428-34
DOI 10.1016/j.radonc.2007.10.012, PubMed 18006097
Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype
BMC Cancer, 7, 116
DOI 10.1186/1471-2407-7-116, PubMed 17603904
Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice
Neoplasia, 9 (5), 392-400
DOI 10.1593/neo.07154, PubMed 17534444
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
Radiat Oncol, 1, 25
DOI 10.1186/1748-717X-1-25, PubMed 16887021
DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
Anticancer Res, 26 (3A), 1909-16
PubMed 16827124
Matrix metalloproteinases participate in osteosarcoma invasion
J Surg Res, 127 (2), 151-6
DOI 10.1016/j.jss.2004.12.016, PubMed 16083752
Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice
Eur J Cancer, 40 (10), 1593-8
DOI 10.1016/j.ejca.2004.02.023, PubMed 15196545
Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum
Tumour Biol, 25 (1-2), 31-40
DOI 10.1159/000077721, PubMed 15192310
Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer
J Pathol, 200 (5), 589-95
DOI 10.1002/path.1381, PubMed 12898594
Detection of disseminated tumour cells in bone marrow of patients with isolated liver metastases from colorectal cancer
J Surg Oncol, 82 (4), 224-7
DOI 10.1002/jso.10223, PubMed 12672004
Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients
Clin Cancer Res, 8 (2), 444-9
PubMed 11839662
[Postoperative wound infections in elective colorectal surgery]
Tidsskr Nor Laegeforen, 120 (23), 2761-3
PubMed 11107920
Review articles
Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei
Pleura Peritoneum, 8 (1), 1-9
DOI 10.1515/pp-2022-0200, PubMed 37020469
Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review
J Gastrointest Oncol, 12 (Suppl 1), S191-S203
DOI 10.21037/jgo-20-136, PubMed 33968437
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies
Crit Rev Oncol Hematol, 95 (1), 114-24
DOI 10.1016/j.critrevonc.2015.01.003, PubMed 25624177
A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome
Annu Rev Genet, 49, 213-42
DOI 10.1146/annurev-genet-120213-092023, PubMed 26473382
Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks
Int J Mol Sci, 15 (12), 22835-56
DOI 10.3390/ijms151222835, PubMed 25501337
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
J Enzyme Inhib Med Chem, 30 (5), 689-721
DOI 10.3109/14756366.2014.966704, PubMed 25347767
Molecular modelling and simulations in cancer research
Biochim Biophys Acta, 1836 (1), 1-14
DOI 10.1016/j.bbcan.2013.02.001, PubMed 23416097
MicroRNAs as biomarkers in colorectal cancer
Am J Pathol, 177 (4), 1592-9
DOI 10.2353/ajpath.2010.100024, PubMed 20829435
Other articles
A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer
bioRxiv
DOI 10.1101/2023.05.17.541233, PubMed 38328254
ASO Author Reflections: Navigation-Assisted Surgery for Locally Advanced and Recurrent Rectal Cancer: The NAVI-LARRC Trial
Ann Surg Oncol, 30 (12), 7633-7634
DOI 10.1245/s10434-023-14058-2, PubMed 37573284
Antitumor activity of intraperitoneal paclitaxel in orthotopic patient-derived xenograft models of mucinous appendiceal adenocarcinoma
bioRxiv
DOI 10.1101/2023.02.01.526672, PubMed 36993681
Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
J Control Release, 349, 1
DOI 10.1016/j.jconrel.2022.06.040, PubMed 35792388
ASO Author Reflections: The Peritoneum is an Active Immunological Compartment
Ann Surg Oncol, 28 (9), 5263-5264
DOI 10.1245/s10434-021-10036-8, PubMed 33939046
Correction to: Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of highgrade pseudomyxoma peritonei
Clin Exp Metastasis, 38 (2), 253
DOI 10.1007/s10585-021-10084-0, PubMed 33649933
ASO Author Reflections: Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method
Ann Surg Oncol, 27 (Suppl 3), 771-772
DOI 10.1245/s10434-020-08691-4, PubMed 32495284
MirGeneDB 2.0: the metazoan microRNA complement
Nucleic Acids Res, 48 (D1), D1172
DOI 10.1093/nar/gkz1016, PubMed 31642479
Corrigendum to "Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer" [Transl Oncol 12 (8) (2019) 1038-1044]
Transl Oncol, 13 (1), 122-124
DOI 10.1016/j.tranon.2019.09.005, PubMed 31843135
Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients (vol 33, pg 73, 2012)
Tumor Biol., 33 (4), 1263-1264
DOI 10.1007/s13277-012-0407-2
Radiosensitizing drugs: lessons to be learned from the oxaliplatin story
J Clin Oncol, 28 (29), e577-8; author reply e581-3
DOI 10.1200/JCO.2010.30.0921, PubMed 20733124
HDAC2 deficiency and histone acetylation
Nat Genet, 40 (7), 812-3; author reply 813
DOI 10.1038/ng0708-812, PubMed 18583969
Theses
Studies of colorectal cancer metastasis
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 200, 1 b. (flere pag.)
BIBSYS 041949617, ISBN 82-8072-144-4